Literature DB >> 17342551

Experimental evaluation of early and long-term effects of microparticle embolization in two different mini-pig models. Part II: liver.

S Stampfl1, U Stampfl, C Rehnitz, Ph Schnabel, S Satzl, P Christoph, C Henn, F Thomas, G M Richter.   

Abstract

PURPOSE: To evaluate trisacryl-gelatin microspheres (40-120 microm) for acute and chronic tissue embolization in mini-pig livers.
METHODS: Thirteen animals were divided into four groups: group 1 (n = 3), total arterial bed occlusion with acute procedure; groups 2 to 4, chronic superselective embolization with follow-up of 1 week (group 2, n = 1), 4 weeks (group 3, n = 4) or 14 weeks (group 4, n = 5). Key endpoints were homogeneity and particle distribution in acute embolizations (group 1) and necrosis and inflammation in chronic embolizations (groups 2-4) as assessed microscopically and angiographically.
RESULTS: After liver embolization, parenchymal necrosis did not occur; only signs of vessel wall disintegration were evident. The bile ducts remained intact. A distinct foreign body reaction with sparse leukocytic infiltration and giant cells was found at 14 weeks, but no signs of major inflammation were found. Particles were seen at the presinusoidal level, but no particle transportation into the sinusoids was observed.
CONCLUSIONS: Embolization in mini-pig livers, using small trisacryl-gelatin microspheres, results in vessel fibrosis without parenchymal or bile duct necrosis. The most likely explanation for preservation of the parenchyma is portal inflow. Small trisacryl-gelatin microspheres may be ideal as an adjunct for chemoembolization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17342551     DOI: 10.1007/s00270-005-0350-3

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  7 in total

Review 1.  Current status of embolic agents for liver tumor embolization.

Authors:  Keigo Osuga; Noboru Maeda; Hiroki Higashihara; Shinichi Hori; Tetsuro Nakazawa; Kaishu Tanaka; Masahisa Nakamura; Kentaro Kishimoto; Yusuke Ono; Noriyuki Tomiyama
Journal:  Int J Clin Oncol       Date:  2012-07-18       Impact factor: 3.402

2.  Transarterial embolization of hypervascular tumors using trisacryl gelatin microspheres (Embosphere): a prospective multicenter clinical trial in Japan.

Authors:  Keigo Osuga; Yasuo Nakajima; Miyuki Sone; Yasuaki Arai; Yoshihiro Nambu; Shinichi Hori
Journal:  Jpn J Radiol       Date:  2016-03-10       Impact factor: 2.374

3.  Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model.

Authors:  Sanjay Gupta; Kenneth C Wright; Joe Ensor; Carolyn S Van Pelt; Katherine A Dixon; Vikas Kundra
Journal:  Cardiovasc Intervent Radiol       Date:  2011-04-09       Impact factor: 2.740

Review 4.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

5.  Therapeutic efficacy of transarterial chemo-embolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma.

Authors:  Kazuhiro Kasai; Akira Ushio; Yukiho Kasai; Kei Sawara; Yasuhiro Miyamoto; Kanta Oikawa; Yasuhiro Takikawa; Kazuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

6.  Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy.

Authors:  Kwang-Hun Lee; Eleni Liapi; Josephina A Vossen; Manon Buijs; Veronica Prieto Ventura; Christos Georgiades; Kelvin Hong; Ihab Kamel; Michael S Torbenson; Jean-Francois H Geschwind
Journal:  J Vasc Interv Radiol       Date:  2008-08-27       Impact factor: 3.464

7.  Computed tomography and histopathological findings after embolization with inherently radiopaque 40μm-microspheres, standard 40μm-microspheres and iodized oil in a porcine liver model.

Authors:  Dominik F Vollherbst; Theresa Gockner; Thuy Do; Kerstin Holzer; Carolin Mogler; Paul Flechsig; Alexander Harms; Christopher L Schlett; Philippe L Pereira; Götz M Richter; Hans U Kauczor; Christof M Sommer
Journal:  PLoS One       Date:  2018-07-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.